Last Updated:

OVAVAX American Biotech Company, On Monday Announced That It Has Started The Phase 1/2

ovavax, an American biotech company, on Monday announced that it has started the phase 1/2 clinical trial of its experimental coronavirus vaccine, joining a han

Written By
KAVYAE M

ovavax, an American biotech company, on Monday announced that it has started the phase 1/2 clinical trial of its experimental coronavirus vaccine, joining a handful of candidates that are currently being tested on humans globally. The trial aims to assess whether the COVID-19 vaccine candidate, NVX‑CoV2373, is safe and generates an immune response in people. It is a vaccine engineered from the genetic sequence of SARS‑CoV‑2 virus that causes CVOID-19.

Maryland-based firm, a late-stage biotechnology firm developing next-generation vaccines for serious infectious diseases, is developing a subunit vaccine using its proprietary nanoparticle technology, Matrix‑M adjuvant, to enhance immune responses and stimulate high levels of neutralizing antibodies. Novavax said the phase 1/2 clinical trial is being conducted in two parts. The company is enrolling approximately 130 healthy participants (18 to 59 years of age) at two sites in Australia for the trial. Novavax expects to share clinical trial results in July.

According to Novavax, the phase 1 portion is a randomised, observer-blinded, placebo-controlled trial designed to evaluate the immunogenicity and safety of the vaccine, NVX‑CoV2373 - both adjuvanted with Matrix‑M and unadjuvanted. While some participants will receive the experimental vaccine, others will get a placebo.

The trial will also test two different dosages of the vaccine (5 and 25 micrograms), and will also test both with and without Matrix‑M. It the vaccine shows promising results, Nonavax said it will quickly move into the phase 2 portion of the trial which will be conducted in multiple countries, including the US.

ovavax, an American biotech company, on Monday announced that it has started the phase 1/2 clinical trial of its experimental coronavirus vaccine, joining a handful of candidates that are currently being tested on humans globally. The trial aims to assess whether the COVID-19 vaccine candidate, NVX‑CoV2373, is safe and generates an immune response in people. It is a vaccine engineered from the genetic sequence of SARS‑CoV‑2 virus that causes CVOID-19.

Maryland-based firm, a late-stage biotechnology firm developing next-generation vaccines for serious infectious diseases, is developing a subunit vaccine using its proprietary nanoparticle technology, Matrix‑M adjuvant, to enhance immune responses and stimulate high levels of neutralizing antibodies. Novavax said the phase 1/2 clinical trial is being conducted in two parts. The company is enrolling approximately 130 healthy participants (18 to 59 years of age) at two sites in Australia for the trial. Novavax expects to share clinical trial results in July.

According to Novavax, the phase 1 portion is a randomised, observer-blinded, placebo-controlled trial designed to evaluate the immunogenicity and safety of the vaccine, NVX‑CoV2373 - both adjuvanted with Matrix‑M and unadjuvanted. While some participants will receive the experimental vaccine, others will get a placebo.

The trial will also test two different dosages of the vaccine (5 and 25 micrograms), and will also test both with and without Matrix‑M. It the vaccine shows promising results, Nonavax said it will quickly move into the phase 2 portion of the trial which will be conducted in multiple countries, including the US.

First Published: